PD1 Resistance with a Multi-Omic Approach

Anti-PD-1 therapy has transformed cancer care but most patients do not respond. It is increasingly clear that there will be no single biomarker of response to a PD-1, and that a multi-omic approach will be required. In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Danny Wells, Parker Institute for Cancer Immunotherapy will address: Orthogonality and correlation of response biomarkers across histologiesIntegration of multi-omic data sets for mechanistic insights into tumor immunobiologyThe translational approaches to PD1 resistance program at the Parker Institute To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com